Literature DB >> 11607775

Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia.

T Ueda1, K Hatanaka, S Kosugi, B I Kishino, T Tamaki.   

Abstract

We report a 62-year-old male who underwent non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) because of his life-threatening severe pancytopenia due to refractory Waldenström's macroglobulinemia. This therapy was performed safely and he made a marked recovery from his cytopenia that had not been improved with any other therapy. Bone marrow aspirates showed post-transplant mixed chimerism during engraftment, and became completely donor-derived after a series of GVHD symptoms, without subsequent donor lymphocyte infusion. Our results suggest that non-myeloablative allogeneic PBSCT could be a good alternative for patients suffering from multi-drug resistant Waldenström's macroglobulinemia.

Entities:  

Mesh:

Year:  2001        PMID: 11607775     DOI: 10.1038/sj.bmt.1703190

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Alice Garnier; Marie Robin; Fabrice Larosa; Jean-Louis Golmard; Steven Le Gouill; Valérie Coiteux; Reza Tabrizi; Claude-Eric Bulabois; Victoria Cacheux; Mathieu Kuentz; Brigitte Dreyfus; Peter Dreger; Bernard Rio; Marie-Pierre Moles-Moreau; Karin Bilger; Jacques-Olivier Bay; Véronique Leblond; Didier Blaise; Olivier Tournilhac; Nathalie Dhédin
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.